Asahi Kasei Therapeutics
June 24, 2026
Theater 4
Type: Company Presentation
Focus Area:
Orphan and Rare Disease
Asahi Kasei has built a global presence in the pharmaceutical sector through strategic acquisitions and investments. Since 2020, we have acquired Veloxis, a company specializing in solid organ transplantation, Calliditas, a company specializing in kidney diseases and rare diseases, and Aicuris, a company specializing in severe infectious diseases. These acquisitions along with various other business development initiatives are driving the growth of our global pharmaceutical business.
Under the “One Pharma” initiative, Asahi Kasei’s pharmaceutical sector seeks further growth in providing innovative therapeutic solutions to patients worldwide. Our core goal is to become a leading specialty pharma in immunology, nephrology, and transplantation and its adjacent areas.
We will continue to focus on the growth of our business through M&A, licensing, and strategic investments and seek partnerships that align with our long-term goals and remain opportunistic for any future M&A opportunities.
Company HQ City:
Chiyoda-ku
Company HQ State:
Tokyo
Company HQ Country:
Japan
Year Founded:
1920
Lead Product in Development:
ART-123
CEO
Yoshikazu Aoki
Development Phase of Lead Product
Multiple Products in Market
Exchange
TYO
Ticker
3407
When you expect your next catalyst update?
-
What is your next catalyst (value inflection) update?
-
Primary Speaker
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}